Abbott announced that it has secured CE Mark (Conformité Européenne) for its next-generation FreeStyle Libre 3 system, which is now approved for use by people living with diabetes in Europe.
The FreeStyle Libre 3 technology provides continuous, real-time glucose readings automatically delivered to smartphones every minute, offering unsurpassed 14-day accuracy in the smallest and thinnest sensor design at the same affordable price as previous versions of the device.
With a 14-day wear time, the FreeStyle Libre 3 system includes the longest-lasting, self-applied CGM sensor available. The sensor is easy to apply with a one-piece applicator and is worn on the back of the upper arm, eliminating the need for painful fingersticks to view glucose levels.
To allow as many people as possible living with diabetes to access and benefit from the significant advancements of the technology, Abbott’s FreeStyle Libre 3 system will be priced the same as previous generations of the device.
The sensor system includes the FreeStyle Libre 3 mobile app, which is designed to enable users to capture and view their real-time glucose levels, glucose history and trend arrows showing how their glucose is changing with just a glance at their smartphone.
Abbott designed its next-generation FreeStyle Libre 3 system to be more sustainable for the environment with a smaller and more discreet sensor, reducing the total volume by more than 70%. With a 41% reduction in plastic use and 43% reduction in carton paper, the new sensor design aligns with the company’s continued commitment to sustainability.
Abbott is launching the FreeStyle Libre 3 system in Europe in the coming months. The FreeStyle Libre portfolio has been clinically proven to improve glucose control, increase time in target glucose range, decrease time in hyperglycemia (high glucose levels) and hypoglycemia (low glucose levels), and lower HbA1c (average glucose levels over a three-month period) – all factors contributing to better health outcomes. Data also show use of the FreeStyle Libre system reduces diabetes-related hospital admissions and work absentee rates to help improve quality of life.
Not available in the UK as of May 21